MEN1 and acute leukemia: The food effects, safety and tolerability of JNJ-75276617, a menin inhibitor from Janssen Pharmaceuticals, is being evaluated in a phase I trial inclusive of adults with R/R KMT2A-r and NPM1c acute leukemias (NCT04811560), and will also be evaluated in a combination regimen with venetoclax or/and azacytidine (NCT05453903).